Pathways to key therapies: Longitudinal claims data reveal relatively consistent use patterns of key therapies among recently treated patients. Which therapies have experienced market growth or decline over the key therapy periods studied? To what extent are key therapies prescribed concomitantly to recently treated patients? What has been the impact of recently approved drugs for DME? Scope:
Primary patient-level data: This report provides quantitative findings from our analysis of data covering approximately 40 million lives and provides the most representative sample of U.S. treatment practice for Medicare and commercially insured patients. This report is delivered as a key findings slide deck and a dashboard that can be accessed using the Internet. It presents claims that are 6-12 months old at time of publication.
Patient Sample: Patients who are continuously enrolled for the complete two-year study period must meet the following condition: at least one claim with a diagnosis code for DME (International Classification of Diseases, Ninth Revision [ICD-9] diagnostic codes 362.07, 250.50) during the study period.
Quantified lines of therapy analyses show exact share of each agent in each line of therapy, including rate of progression between lines and length of time patients are on each line.
Newly diagnosed patients:
-Patient share by drug class and key products across three lines of therapy, within one year of diagnosis.
-Patient flowcharts through one year of treatment for all first-line products, including progression rates and add/switch behavior.
-Polypharmacy and key concomitant therapies by line of therapy.
-Quarterly trending of patient share by line of therapy.
Recently treated patients:
-Quarterly snapshot of patient share by drug class and key products.
-Pathway to key therapy flowcharts tracking the preceding therapy patterns for all key therapies, including add/switch behavior.
-Brand source of business including share for continuing, new (switches/adds), and new (initial therapy) business.
-Polypharmacy and key concomitant therapies.
-Drug persistence and compliance.
-Quarterly trending of patient share for all key therapies.
